Dr. Stephen Spielberg is a professor of pediatrics and of pharmacology and toxicology at Dartmouth Medical School, where he also served as dean from 2003 to 2007. He is the principal investigator for the Institute for Pediatric Innovation's (IPI's) Pediatric Pharmaceutical Reformulation Project. His career in pediatric clinical pharmacology and human pharmacogenetics has included faculty and leadership positions at Johns Hopkins School of Medicine, the Hospital for Sick Children in Toronto, Merck Research Laboratories, and as vice president of Pediatric Drug Development at Johnson & Johnson. Dr. Spielberg was chair of the Pediatric Task Force for the Pharmaceutical Research and Manufacturers of America (PhRMA), represented the pharmaceutical industry on the FDA Pediatric Advisory Subcommittee and on pediatric legislative initiatives in the US and EU, and was the rapporteur for the Pediatric ICH Initiative, ICH E-11.

Dr. Spielberg has served as editor or on the editorial board of numerous journals, is on the board of directors of the Foundation for the National Institutes of Health, chairs the Pediatric Pharmacology Unit Advisory Board for the National Institute of Child Health and Human Development (NICHD), and was president of the American Society for Clinical Pharmacology and Therapeutics (2006).

Dr. Spielberg received an AB (Biology) from Princeton University, an MD and PhD (Pharmacology) from the University of Chicago, served a pediatric internship and residency at Children's Hospital, Boston, and a post-doctoral fellowship in human biochemical genetics at NICHD. He is the recipient of many awards for his contributions to pediatric therapeutics and adverse drug reaction research.